Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
Clinics ; 71(8): 435-439, Aug. 2016. tab
Article in English | LILACS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: lil-794635

ABSTRACT

OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness of LDE-paclitaxel on inpatients with aortic atherosclerosis. METHODS: This study tested a 175 mg/m2 body surface area dose of LDE-paclitaxel (intravenous administration, 3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed. RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at 1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the LDE-paclitaxel group and one death occurred in the control group. CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed the potential to reduce atherosclerotic lesion size.


Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Aortic Diseases/drug therapy , Cholesterol/therapeutic use , Paclitaxel/therapeutic use , Atherosclerosis/drug therapy , Tubulin Modulators/therapeutic use , Nanoparticles/therapeutic use , Aorta, Thoracic/drug effects , Aortic Diseases/diagnostic imaging , Time Factors , Triglycerides/blood , Angiography , Cholesterol/blood , Reproducibility of Results , Treatment Outcome , Drug Delivery Systems , Atherosclerosis/diagnostic imaging , Fat Emulsions, Intravenous/therapeutic use , Multidetector Computed Tomography
3.
The Korean Journal of Gastroenterology ; : 172-176, 2012.
Article in English | WPRIM | ID: wpr-47304

ABSTRACT

We report herein a case of intestinal amyloidosis with grave prognosis that caused intractable diarrhea and intestinal pseudo-obstruction, alternately in spite of intensive conservative treatment. A 44-year-old woman was admitted for fever, diarrhea, and crampy abdominal pain which had been continuned during 6 months. Abdomen CT scan showed edematous wall thickening of the small bowel and right colon, and colonoscopic biopsy revealed amyloid deposition in the mucosa. Monoclonal light chains in serum and/or urine were not detected and highly elevated serum amyloid A was shown. In spite of intensive treatment including oral prednisolone and colchicine, diarrhea and intestinal pseudo-obstruction developed alternately, general status rapidly got worsened and died after two months.


Subject(s)
Adult , Female , Humans , Administration, Oral , Amyloidosis/complications , Anti-Inflammatory Agents/therapeutic use , Colchicine/therapeutic use , Colonoscopy , Diarrhea/etiology , Intestinal Mucosa/pathology , Intestinal Pseudo-Obstruction/diagnosis , Prednisolone/therapeutic use , Serum Amyloid A Protein/metabolism , Tomography, X-Ray Computed , Tubulin Modulators/therapeutic use
4.
Article in English | IMSEAR | ID: sea-93635

ABSTRACT

Behçet's disease (BD) is a multi-system inflammatory disorder which presents with recurrent orogenital ulceration, uveitis, and erythema nodosum. Medium vessel vasculitis of upper limb is extremely rare and it is only reported in patients with Behçet's disease on long follow up. Mean duration from diagnosis of disease to development of vasculitis is 5.8 years. We present a patient who presented with gangrene of fingers with absent radial pulse and during course of his illness he developed features of Behçet's disease. Diagnosis was established by clinical features and histopathology and patient was treated with steroids and colchicine.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Arterial Occlusive Diseases/diagnosis , Behcet Syndrome/diagnosis , Colchicine/therapeutic use , Erythema Nodosum/physiopathology , Humans , Inflammation , Male , Middle Aged , Radial Artery/pathology , Tubulin Modulators/therapeutic use , Uveitis/physiopathology , Vasculitis/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL